In this column, I’ll be highlighting some of the research presented at this year’s Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum, held last week in West Palm Beach, Florida.
You’ll need to read to the end of this news story to get to the most interesting information. The researchers’ data indicate that human glial progenitor cells can be transplanted into areas of the central nervous systems of mice where myelin has been damaged, to remyelinate them. It’s worth a long read to see how the researchers support their conclusions.
Transplanting human glial progenitor cells (GPCs) — brain cells able to generate myelin-producing cells — effectively led to remyelination in the brains of adult mice with myelin disorders, a study found.
These results were presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2020, running Feb 27–29 in Florida, by John Mariani, PhD, with the University of Rochester.
His presentation was titled “Human Glial Progenitor Cells Effectively Remyelinate The Demyelinated Adult Brain.”
Click here to read the full story.
Here’s another early study about myelin. This one involves an agent that’s designed to increase energy reserves within neurons and myelin-producing cells, or oligodendrocytes, while decreasing toxic metabolic byproducts. It’s expected that the process will improve the survival and function of those neurons and support the ability of oligodendrocytes to create new myelin.
Clene Nanomedicine shared early results of the VISIONARY-MS trial, suggesting that CNM-Au8 — an investigational remyelinating therapy — leads to “notable” trends in better vision, as well as benefits in mobility and manual function in relapsing multiple sclerosis (MS) patients with chronic vision problems.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?